Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The efficacy of short-course blinatumomab immunotherapy as a bridge-to-HSCT in ph-negative B-cell acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

XSXiangqi ShaoLWLiping Wan

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows blinatumomab reduces relapse rates and chronic GVHD in B-ALL patients before HSCT.

Key Points

  • Evaluate the efficacy of short-course blinatumomab as a pre-HSCT treatment in Ph-negative B-ALL patients.
  • Retrospective analysis of 70 Ph-B-ALL patients undergoing allo-HSCT.
  • Patients received short-course blinatumomab or conventional chemotherapy before transplant.
  • End points included 18-month relapse-free survival (RFS) and overall survival (OS) rates.
  • All patients achieved MRD-negative status before allo-HSCT.
  • Blinatumomab cohort had higher 18-month RFS (78.5% vs 55%) compared to chemotherapy (p = .033).
  • Blinatumomab reduced chronic GVHD incidence (10.14% vs 35.8%, p = .05) compared to chemotherapy.

Cite This Study

Shao et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8b1https://doi.org/10.1182/blood-2025-6078
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparing the impact of blinatumomab therapy versus standard chemotherapy on the progression of relapsed/refractory pediatric B-ALL: a two-center retrospective cohort study2026
  2. 2Blinatumomab before and after allogeneic hematopoietic stem cell transplantation in adult patients with B-cell acute lymphoblastic leukemia2025
  3. 3Bispecific monoclonal antibody blinatumomab in the first-line therapy of B-lineage acute lymphoblastic leukemia in children and adolescents: interim results of the Russian Ministry of Health approbation protocol2024
  4. 4Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL2024 · 13 citations
  5. 5Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity2025